Lokavant

About Lokavant

Lokavant operates as a clinical trial intelligence company, providing a platform to decrease the time and cost associated with developing new drugs. Founded in 2019 by CEO Rohit Nambisan, the company was incubated within Roivant Sciences before officially launching as a separate entity. Nambisan, a trained neuroscientist with a background in health IT, data analytics, and AI, leveraged his experience to address the operational inefficiencies he observed firsthand within a sponsor organization. This led to the creation of a platform designed to be battle-tested before its external launch.

The firm's core business revolves around its Clinical Intelligence Platform, which serves pharmaceutical companies and contract research organizations (CROs). This platform addresses the challenge of data fragmentation in clinical trials by ingesting, harmonizing, and analyzing real-time data from numerous disparate sources. By creating a single source of truth, Lokavant provides clients with real-time visualizations, risk alerts, and predictive analytics to improve decision-making throughout a trial's lifecycle, from planning to closeout. Revenue is generated through enterprise license agreements for its software-as-a-service (SaaS) platform and its suite of modular solutions.

Lokavant's product portfolio includes several key applications. Spectrum™, an AI-powered software, focuses on trial feasibility, allowing study teams to predict, optimize, and control trial timelines and budgets by running thousands of simulations in minutes. Other solutions include Study Oversight for real-time performance monitoring, Risk Detection using predictive analytics, and modules for Dynamic Enrollment forecasting and Medical Monitoring. The platform is built upon a proprietary dataset from over 2,000 historical trials and integrated with real-world data sources, enabling it to deliver forecasts with high accuracy. This data-driven approach has shown to save millions in costs from patient retention and months in time savings by detecting site non-compliance issues earlier than traditional methods.